^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Auraza (chiauranib)

    i
    Other names: CS 2164, CS2164, CS-2164
    Company:
    Chipscreen
    Drug class:
    VEGFR inhibitor, CSF-1R inhibitor, Aurora kinase B inhibitor
    Related drugs:
    2ms
    DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma. (PubMed, Ann Hematol)
    Besides, downregulating the levels of c-Myc, BCL-xL and MCL-1 also contributed to the synergistic effects of the combined regimen on t-FL. Taken together, these findings suggest that the synergy between the DGKα inhibitor ritanserin and multi-targeted inhibitor chiauranib might represent a promising option for the treatment of t-FL.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    Auraza (chiauranib)
    8ms
    Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) (clinicaltrials.gov)
    P2, N=40, Completed, Chipscreen Biosciences, Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Auraza (chiauranib)
    8ms
    Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Recruiting, Chipscreen Biosciences, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • albumin-bound paclitaxel • Auraza (chiauranib)
    9ms
    AK104-212: A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=36, Completed, Akeso | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    ATRX (ATRX Chromatin Remodeler)
    |
    Kaitanni (cadonilimab) • Auraza (chiauranib)
    12ms
    Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=184, Completed, Chipscreen Biosciences, Ltd. | Recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2024 | Trial primary completion date: Dec 2024 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Auraza (chiauranib)
    1year
    Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=180, Recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    Auraza (chiauranib)
    1year
    A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (clinicaltrials.gov)
    P2, N=9, Terminated, Chipscreen Biosciences, Ltd. | N=38 --> 9 | Recruiting --> Terminated; During the enrollment period of this project, due to the increasing proportion of patients receiving capecitabine adjuvant therapy and the large number of trials competing for the same number of lines in various centers
    Enrollment change • Trial termination • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative • PGR negative
    |
    capecitabine • Auraza (chiauranib)
    over1year
    Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer (clinicaltrials.gov)
    P3, N=180, Recruiting, Chipscreen Biosciences, Ltd. | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date
    |
    Auraza (chiauranib)
    over1year
    A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (clinicaltrials.gov)
    P2, N=38, Recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    capecitabine • Auraza (chiauranib)
    over1year
    Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Chipscreen Biosciences, Ltd. | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Auraza (chiauranib)
    over1year
    Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Chipscreen Biosciences, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    Auraza (chiauranib)
    over1year
    Mass Balance Study of [14C]Chiauranib (clinicaltrials.gov)
    P=N/A, N=6, Completed, Chipscreen Biosciences, Ltd. | Recruiting --> Completed | Trial primary completion date: Nov 2023 --> Mar 2024
    Trial completion • Trial primary completion date
    |
    Auraza (chiauranib)